Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 77 | SFEBES2021 | Next issue

Society for Endocrinology BES 2021

Edinburgh, United Kingdom
08 Nov 2021 - 10 Nov 2021

Card image cap
Join us in Edinburgh for the flagship event of the Society for Endocrinology

Oral Communications

Endocrine Cancer and Late Effects

ea0077oc2.1 | Endocrine Cancer and Late Effects | SFEBES2021

Outcomes of surgery and treatment with selective RET TK inhibitor Selpercatinib in children with MEN2 and advanced MTC.

Kurzawinski Tom , Hubbard Jonathan , Abdel Aziz Tarek , Butler Colin , Brain Caroline , Beale Tim , Gaze Mark , Ross Emma , Stoneham Sarah , Hulse Tony , Simpson Kate , Proctor Ian , Cattaneo Elene , Gevers Evelien , Marshall Lynley , Shankar Ananth

Background: Patients with Multiple Endocrine Neoplasia type 2 (MEN2) without previous family history often present late with advanced Medullary Thyroid Cancer (MTC). Surgery is not always curative but RET tyrosine kinase pathway is a potential target for molecular treatment for progressive MTC.Methods: Retrospective review of clinical, genetic, biochemical (calcitonin, CEA) and imaging (US, CT/MRI, Gallium Dotate) data of children with MEN2 who developed...

ea0077oc2.2 | Endocrine Cancer and Late Effects | SFEBES2021

An emerging role for proteostasis modulators targeting NIS activity to enhance radioiodide therapy in thyroid cancer

Read Martin , Brookes Katie , Thornton Caitlin , Nieto Hannah , Zha Ling , Fletcher Alice , Boelaert Kristien , Smith Vicki , McCabe Christopher

Introduction: New therapeutic strategies are urgently needed to improve radioiodide (RAI) uptake and efficiently ablate thyroid cancer cells, thereby reducing the risk of recurrent disease. We recently utilised high throughput screening and identified FDA-approved compounds capable of inducing sodium iodide symporter (NIS) function to enhance iodide uptake. Categorisation revealed a high proportion of drugs that modulate proteostasis, with 6 of the top 15 targeting activity of...

ea0077oc2.3 | Endocrine Cancer and Late Effects | SFEBES2021

A novel in vivo platform for studying tumour vascularization and endocrine responses

Lopes Tatiana , Prague Julia , Salem Victoria , Owen Bryn

Background: Tumour growth is critically dependent on blood perfusion, its source of oxygen and nutrients. Therefore, tumour vascularization has become an attractive target for the treatment of many cancers types. The study of endocrine-responsive tumours, in particular, needs improved platforms to screen drugs targeting vascularization that have better resolution and that do not compromise on inter-individual variability.Aim: Hence, we’ve set out to...

ea0077oc2.4 | Endocrine Cancer and Late Effects | SFEBES2021

PBF phosphorylation regulates cell motility of thyroid and breast cancer cells

Kocbiyik Merve , Alshahrani Mohammed , Poole Vikki L , Jeyanathan Sakaorna , Thornton Caitlin , Zha Ling , Brookes Katie , Nieto Hannah , Read Martin L , McCabe Chris J , Smith Vicki E

The proto-oncogene pituitary tumor transforming gene binding factor (PTTG1IP/PBF) is overexpressed in multiple tumours and associated with tumour progression. One of the tumourigenic processes that PBF can mediate is cell motility. PBF can induce cell invasion in both thyroid and breast cancer cell lines. However, in contrast to wild-type (WT) PBF, the Y174A PBF mutant was not able to induce the invasiveness of thyroid or breast cancer cells. The Y174 residue is highly phospho...

ea0077oc2.5 | Endocrine Cancer and Late Effects | SFEBES2021

A novel MiR-346-Directed DNA damage mechanism is regulated by its interaction with long non-coding RNA, NORAD, in prostate cancer

Fletcher Claire , Orafidiya Folake , Deng Lin , Yuan Wei , Lorentzen Marc , Cyran Oliwia , Varela-Carver Anabel , Constantin Theodora , Dobbs Felix , Figueiredo Ines , Gurel Bora , Parkes Eileen , Bogdan Denisa , Pereira Ronnie , Zhao Shuang (George) , Neeb Antje , Issa Fadi , Hester Joanna , Kudo Hiromi , Liu Yang , Philippou Yiannis , Bristow Robert , Knudsen Karen , Bryant Richard , Feng Felix , Reed Simon , Mills Ian , de Bono Johann , Bevan Charlotte

MiR-346 is an Androgen Receptor (AR)-activating miR that associates with DNA damage response (DDR)-linked transcripts in prostate cancer (PC). MiR-346 induces rapid and extensive DNA damage in PC cells through chromatin association, activation of transcription, R-loop formation and DNA replication stress, leading to checkpoint activation and cell cycle arrest. MiR-346 interacts with lncRNA, NORAD, in PC cells, which functions to maintain mitosis, DDR, and chromosomal integrity...

ea0077oc2.6 | Endocrine Cancer and Late Effects | SFEBES2021

Transcriptomic analysis of succinate dehydrogenase subunit deleted cells to identify molecular mechanisms underlying the increased metastatic potential of SDHB-deficient tumours

Salsbury Grace , Hall Charlotte , Lim Eugenie , Read Jordan , Akker Scott , Chapple Paul

Mutations in each of the 4 subunits of succinate dehydrogenase (SDH) – SDHA, B, C and D predispose to development of phaeochromocytomas and paragangliomas. Loss of SDH function leads to accumulation of succinate which acts as an oncometabolite to drive tumourigenesis. However, mutations in SDHB have an increased likelihood of causing metastatic disease, compared to mutations in the other SDH subunits. The reasons behind this increased risk remai...